European Society of Cardiology

Nearly 4,600 abstracts were presented at the European Society of Cardiology Congress 2014 in Barcelona, Spain, which represented new findings and advancements throughout all areas of the field of cardiology.

BARCELONA, Spain — Patients with atrial fibrillation who used digoxin at baseline in the ROCKET AF trial had increased risks for all-cause mortality, vascular mortality and sudden cardiac death.

BARCELONA, Spain — In a subgroup analysis of the ENGAGE AF-TIMI 48 trial, patients with clinical factors known to increase risk for bleeding due to higher drug exposure who were administered a reduced edoxaban dose had decreased drug concentrations and anti-factor Xa activity, rates of stroke or systemic embolic events consistent with those who did not receive a dose reduction and greater relative reductions in bleeding compared with warfarin.

BARCELONA, Spain — In a subgroup analysis of the ENGAGE AF-TIMI 48 trial, patients with clinical factors known to increase risk for bleeding due to higher drug exposure who were administered a reduced edoxaban dose had decreased drug concentrations and anti-factor Xa activity, rates of stroke or systemic embolic events consistent with those who did not receive a dose reduction and greater relative reductions in bleeding compared with warfarin.

BARCELONA, Spain — Results of a meta-analysis demonstrate that beta-blockers reduced all-cause mortality in patients with HF and sinus rhythm, but not in those with HF and atrial fibrillation.

BARCELONA, Spain — In patients with persistent atrial fibrillation, pulmonary vein isolation alone resulted in successful outcomes without the need for additional ablation, according to results from the STAR-AF 2 study.

BARCELONA, Spain — Colchicine is not an effective treatment for patients who develop postoperative pericardial effusion, researchers for the POPE-2 study concluded at ESC Congress.

BARCELONA, Spain — Among patients with atrial fibrillation who are taking aspirin but not an anticoagulant, those with permanent atrial fibrillation were twice as likely to have a stroke compared with those with paroxysmal atrial fibrillation, according to data pooled from two trials.

BARCELONA, SPAIN — In this video, Bernard De Bruyne, MD, PhD, of the Cardiovascular Center Aalst, Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium, outlines results from the FAME II trial, presented at the ESC Congress.

BARCELONA, Spain — Local anesthesia was associated with similar safety and efficacy outcomes as general anesthesia in transcatheter aortic valve replacement, according to findings from the FRANCE 2 Registry.